Advertisement
MRI classifier identifies a subset of patients with disease marked by cortical atrophy, not demyelination
A co-author explains some of the key McDonald criteria revisions
The BTK inhibitor tolebrutinib meets its primary endpoint in phase 3 HERCULES trial
Meaningful characterization is critical to advancing research and care, review authors contend
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Guidance from international committee on differential diagnoses and diagnostic approach
New phase 1 trial showcases Neurological Institute’s interdisciplinary study capabilities
It’s time to get familiar with this emerging demyelinating disorder
Heightened awareness of this rare disorder may lead to better diagnosis and treatment progress
Insights on the decision process for selecting a treatment approach
New reports focus on neuroimaging biomarkers and features of atypical presentations
Advertisement
Advertisement